Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP3A5*3 genotype associated with intrasubject pharmacokinetic variation toward tacrolimus in bioequivalence study.

Therapeutic drug monitoring - 1 Feb 2010

Yong Chung Jae, Jung Lee Yoon, Bok Jang Seong, Ahyoung Lim Lay, Soo Park Min, Hwan Kim Kyung

Abstract excerpt

Tacrolimus is metabolized by CYP3A and has highly variable pharmacokinetics. To study the factors contributing to this high variability in pharmacokinetics and to investigate the possibility of genotype-specific clinical applications, the effect of differing CYP3A5 genotypes on the intrasubject c...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Asian People
Share to Cross-Over Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to Immunosuppressive Agents

Share to Randomized Controlled Trials as Topic

Share to Tacrolimus

Source

Identifiers

PMID: 20010459
DOI: 10.1097/FTD.0b013e3181c49a4c

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20010459-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP3A5*3 genotype associated with intrasubject pharmacokinetic variation toward tacrolimus in bioequivalence study.PMID 20010459Read ↗

Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.Semantic proximity Read ↗

Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects.Semantic proximity Read ↗

A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients.Semantic proximity Read ↗

Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients.Semantic proximity Read ↗

CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation.Semantic proximity Read ↗

Effect of CYP3A5*3 polymorphism on pharmacokinetic drug interaction between tacrolimus and amlodipine.Semantic proximity Read ↗

CYP3A5 genotype had no impact on intrapatient variability of tacrolimus clearance in renal transplant recipients.Semantic proximity Read ↗

Tacrolimus Elimination in Four Patients With a CYP 3A5*3/*3 CYP 3A4*22/*22 Genotype CombinationSemantic proximity Read ↗

Effectiveness of Measuring Genetic Polymorphisms in Metabolizing Enzymes of Tacrolimus within One Medical Facility.Semantic proximity Read ↗

Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus.Semantic proximity Read ↗

Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients.Semantic proximity Read ↗

The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.